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Introduction

Varies by Sex and β2-GPI Peptides

The risk of melanoma, a form of skin cancer, increases with age but tanning beds and
other forms of tanning increase the risk for young people too. This deadly cancer kills
almost 10,000 people each year. Skin cancer tumors develop in melanocytes, which
produce the skin pigment. Tumor growth primarily depends on the growth of new blood
vessels (angiogenesis).
β2-GPI, a protein in high concentration in the blood, binds to hypoxic tissues or
damaged endothelial cells. Studies have shown β2-GPI can induce or inhibit
angiogenesis. Peptides 296c-s and RD-p9 were derived from the binding region of β2-GPI
(red line) to inhibit β2-GPI activity.
C3 complement activation is a part of complement cascade that begins inflammation
and is central to complement activation when the antibody, IgM is present. IgM activates
the classical complement pathway and is one of the isotypes in the initial antigen-antibody
complexes. In male mice tissue damage is via IgM recognition of β2-GPI with
complement activation. Clinical studies and other animal models indicate sex hormones
alter vessel dilation during reperfusion β2-GPI binding and complement activation may
differ by sex due to different anatomy between genders. We hypothesize that β2-GPI, C3,
and IgM all play a significant role in melanoma cancer. By blocking β2-GPI we can
significantly decrease melanoma tumor growth.
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β2-GPI Peptides Decreased Melanoma
Tumor Size
Tumor Volume (LxW^2/2)

On the 10th day the melanoma tumors were removed from each mice.
Tumor pictures were recorded for each tumor. Tumors treated with saline
and p16ss appear to be significantly larger than the tumors treated with the
blocking peptides 296c-s and RD-p9. Representative of 4-6 tumors per
peptide.
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Female Melanoma Tumors Express
C3 and IgM
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Melanoma Tumors express C3 and IgM by Immunochemistry. C3
and IgM demonstrated bright fluorescent co-localization on the tumors
that were stained with both the primary and secondary antibodies. The
tumors stained with control antibodies displayed a very dim fluorescent.
This suggest C3 and IgM are both present within a melanoma tumor.
Representative of 4 tumors with 6-8 pictures per tumor.
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Cells:
B16F10 were cultured in DMEM2 with 5% Nu -Serum,
5% FBS, 10%vOpti-mem, and 1x Glutamax in a
humidifier incubator (37oC) with 5% CO2. They were
split 1:5 Mondays and Wednesdays and 1:10 on Fridays.
Melanoma Tumors:
C57BI/6 mice (6-9 weeks old) were bred and maintained
in the Division of Biology at K-State. Mice were kept in
a 12 hour light-dark cycle with constant access to rodent
food and water. The Institutional Animal Care and Use
Committee (IACUC) approved all procedures and
complied with the Animal Welfare Act. Mice were
injected with 2x106 B16F10 cells in Matrigel (1:1) and
tumors were measured daily for 10 days prior to
removing tumors. Peptides were given to mice by retroorbital injection on multiple days during the 10 day
period. Tumor weight and pictures were recorded of each
animal after removal.
β2-GPI and C3 and IgM Immunohistochemistry:
Tissues were incubated with 10% Donkey sera in PBS
for 30 minutes at 37oC to block non-specific antibody
binding. Tissues were covered with a primary antibody
or an appropriate isotype control antibody. The primary
antibody is specific for the antigen and the isotype
antibody serves as a negative control and is not specific.
After washing, a secondary antibody is added to the
slides at room temperature and in darkness to prevent
fluorescence wash out. Slides were then cover slipped.
Pictures were of the taken of the melanoma tumors using
Infinity Analyze program and a Nikon Eclipse 80i
fluorescent microscope.
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Hypothesis
B2–GPI plays a role in hypoxic tissue
damage and that blocking B2–GPI may
decrease tumor growth.
Methods
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Male tumors grew faster and larger than female tumors.
Peptides 296c-s and RD-p9 decreased melanoma tumor
growth and weight suggesting therapeutic potential.
Both C3 and IgM are present in female melanoma tumors.
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Mice were injected with 2x106 B16F10 cells and tumors were measured
each day for 10 days until removed. Tumors were measured daily over
the course of 10 days. The weight of each tumor was recorded on the 10th
day after the removal of the tumor from the mouse. Peptides 296c-s and
RD-p9 showed a significant decrease in tumor growth compared to the
controls saline and p16ss. Males demonstrated a larger growth in both
volume and weight. Representative of 4-7 tumors per peptide.

Future Directions
•
•
•

Increase sample size for C3 and IgM immunochemistry.
Compare C3 and IgM in tumors from males vs females.
Conduct more C3 and IgM IHC with tumors treated with
and without peptides.
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